Literature DB >> 2515234

Effectiveness of short pituitary suppression with gonadotropin-releasing hormone agonist leuprolide during induction of ovulation for in vitro fertilization.

I Henig1, P J Chan, S G Prough, D R Tredway.   

Abstract

A short suppression regimen with daily 0.5 mg leuprolide commencing the first day of in vitro fertilization (IVF) cycles was evaluated in 10 women who previously underwent similar IVF cycle without suppression. Induction of ovulation, oocyte retrieval, incubation, and embryo transfer were similar in all the cycles. Assessment included the amount of human menopausal gonadotropin (hMG) used, length of stimulation, serum estradiol and luteinizing hormone (LH) levels, number of oocytes retrieved and their quality, cleavage rate, and number of embryos. The results showed that when leuprolide was used, no endogenous LH surge was detected, and there was a significant increase in hMG injected, from 19.0 +/- 5.8 to 34.4 +/- 17 ampoules, and in estradiol levels, from 1276 +/- 470 to 2618 +/- 1084 pg/ml (mean +/- SD). In addition, there was an increase in the total oocytes retrieved from 54 to 94, their cleavage rate from 59 to 86%, and the number of embryos from 24 to 70 in the suppressed cycle. No deleterious effects were observed and there were two pregnancies in this group.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2515234     DOI: 10.1007/bf01132864

Source DB:  PubMed          Journal:  J In Vitro Fert Embryo Transf        ISSN: 0740-7769


  18 in total

1.  Use of GnRH analogues in ovulation induction for in vitro fertilization: benefit of a short administration regimen.

Authors:  P Barriere; P Lopes; J P Boiffard; C Pousset; M Quentin; P Sagot; A L'Hermite; M F Lerat; B Charbonnel
Journal:  J In Vitro Fert Embryo Transf       Date:  1987-02

2.  An alternate approach to controlled ovarian hyperstimulation in "poor responders": pretreatment with a gonadotropin-releasing hormone analog.

Authors:  P Serafini; B Stone; J Kerin; J Batzofin; P Quinn; R P Marrs
Journal:  Fertil Steril       Date:  1988-01       Impact factor: 7.329

3.  Successful use of gonadotropin-releasing hormone agonist leuprolide for in vitro fertilization in a patient with polycystic ovarian disease and infertility unresponsive to standard treatment.

Authors:  E Radwanska; R G Rawlins; I Tummon; V Maclin; Z Binor; W P Dmowski
Journal:  Fertil Steril       Date:  1988-02       Impact factor: 7.329

4.  In vitro fertilization: diurnal and seasonal variation in luteinizing hormone surge onset and pregnancy rates.

Authors:  R F Casper; H J Erskine; D T Armstrong; S E Brown; S A Daniel; G R Graves; A A Yuzpe
Journal:  Fertil Steril       Date:  1988-04       Impact factor: 7.329

5.  Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization.

Authors:  S Neveu; B Hedon; J Bringer; J M Chinchole; F Arnal; C Humeau; P Cristol; J L Viala
Journal:  Fertil Steril       Date:  1987-04       Impact factor: 7.329

6.  The effect of different methods of ovarian stimulation for human in vitro fertilization and embryo replacement.

Authors:  J M Vargyas; C Morente; G Shangold; R P Marrs
Journal:  Fertil Steril       Date:  1984-11       Impact factor: 7.329

7.  In vitro fertilization and embryo transfer as related to endogenous luteinizing hormone rise or human chorionic gonadotropin administration.

Authors:  B Lejeune; M Degueldre; M Camus; M Vekemans; L Opsomer; F Leroy
Journal:  Fertil Steril       Date:  1986-03       Impact factor: 7.329

8.  The use of high-dose human menopausal gonadotropin in an in vitro fertilization program.

Authors:  N Laufer; A H DeCherney; F P Haseltine; M L Polan; H C Mezer; A M Dlugi; D Sweeney; F Nero; F Naftolin
Journal:  Fertil Steril       Date:  1983-12       Impact factor: 7.329

9.  NIH conference. Therapeutic applications of luteinizing-hormone-releasing hormone and its analogs.

Authors:  G B Cutler; A R Hoffman; R S Swerdloff; R J Santen; D R Meldrum; F Comite
Journal:  Ann Intern Med       Date:  1985-05       Impact factor: 25.391

10.  Comparison between flare up and down regulation effects of luteinizing hormone-releasing hormone agonists in an in vitro fertilization program.

Authors:  R Frydman; J Belaisch-Allart; I Parneix; R Forman; A Hazout; J Testart
Journal:  Fertil Steril       Date:  1988-09       Impact factor: 7.329

View more
  1 in total

Review 1.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.